Daxor Corp(DXR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 7 at 4:35 PM ET (Korea 10/8 05:35)
Full metrics table
| Index | - | P/E | 8.61 | EPS (ttm) | 1.22 | Insider Own | 49.2% | Shs Outstand | 5.8M | Perf Week | -6.58% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | 85.71% | Insider Trans | 0.03% | Shs Float | 3.0M | Perf Month | 0.48% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -0.04 | Inst Own | 7.23% | Short Float | 0.08% | Perf Quarter | 3.96% |
| Income | 0.01B | P/S | 409.19 | EPS this Y | -320% | Inst Trans | 0.06% | Short Ratio | 0.12 | Perf Half Y | 15.81% |
| Sales | 0.00B | P/B | 1.18 | EPS next 5Y | - | ROA | 14.2% | Short Interest | 0.00M | Perf YTD | -28.75% |
| Book/sh | 8.88 | P/C | 10.6 | EPS past 3/5Y | 13.2% - | ROE | 14.24% | 52W High | -28.78% ($14.76) | Perf Year | -21.83% |
| Cash/sh | 0.99 | P/FCF | - | Sales past 3/5Y | - | ROIC | 12.02% | 52W Low | 22.78% ($8.56) | Perf 3Y | 13.01% |
| Dividend Est. | - | EV/EBITDA | 8.92 | EPS Y/Y TTM | 234.88% | Gross Margin | -106.52% | Volatility(W/M) | 4.84% 7.14% | Perf 5Y | -5.32% |
| Dividend TTM | - | EV/Sales | 370.59 | Sales Y/Y TTM | -85.48% | Oper. Margin | 4024.05% | ATR (14) | 0.71 | Perf 10Y | 26.63% |
| Dividend Ex-Date | 2018/1/5 | Quick Ratio | 245.27 | EPS Q/Q | -791.41% | Profit Margin | 4021.89% | RSI (14) | 45.05 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 245.27 | Sales Q/Q | -93.8% | SMA20 | -5.52% ($11.12) | Beta | 0.39 | Target Price | $20 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -1.56% ($10.68) | Rel Volume | 0.37 | Prev Close | $10.3 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -6.05% ($11.19) | Avg Volume(3M) | 0.02M | Price | $10.51 |
| IPO | 1983/7/25 | Option/Short | No/Yes | Trades | 108 | Volume | 6,981 | Change | 2.04% |
A medical device and diagnostics company revolutionizing heart failure and critical care management through BVA-100, its proprietary precision blood volume measurement technology.
Over the past 1 year, roughly in the middle
29% below its 1-year high.
Traded less than usual That is 37% of its average volume.
DXR makes money exceptionally well
Of every $100 in sales, $4,024.05 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -320.0% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $892. Peers typically go for $1,543.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -5.3%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Institutions barely hold it
Institutions hold 7.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% It ranks #40 of 51 in the industry
Based on market cap of $61M.
FAQ
What kind of company is DXR?
DXR belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of DXR?
The market cap of DXR is approximately $61M, ranking 4,817 within its sector.
What is the P/E ratio of DXR?
DXR has a P/E ratio of approximately 8.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for DXR?
DXR has recorded a 52-week high of $14.76 and a low of $8.56.
